Defining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases.


Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
11 2023
Historique:
received: 15 06 2023
revised: 22 08 2023
accepted: 22 08 2023
medline: 14 11 2023
pubmed: 31 8 2023
entrez: 30 8 2023
Statut: ppublish

Résumé

Biallelic pathogenic variants in PGAP3 cause a rare glycosylphosphatidyl-inositol biogenesis disorder, PGAP3-CDG. This multisystem condition presents with a predominantly neurological phenotype, including developmental delay, intellectual disability, seizures, and hyperphosphatemia. Here, we summarized the phenotype of sixty-five individuals including six unreported individuals from our CDG natural history study with a confirmed PGAP3-CDG diagnosis. Common additional features found in this disorder included brain malformations, behavioral abnormalities, cleft palate, and characteristic facial features. This report aims to review the genetic and metabolic findings and characterize the disease's phenotype while highlighting the necessary clinical approach to improve the management of this rare CDG.

Identifiants

pubmed: 37647829
pii: S1096-7192(23)00318-9
doi: 10.1016/j.ymgme.2023.107688
pii:
doi:

Substances chimiques

PGAP3 protein, human EC 3.1.1.-
Carboxylic Ester Hydrolases EC 3.1.1.-
Receptors, Cell Surface 0

Types de publication

Review Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107688

Subventions

Organisme : NINDS NIH HHS
ID : U54 NS115198
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Ruqaiah Altassan (R)

Department of Medical Genomics, Centre for Genomics Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Michael M Allers (MM)

Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States.

Diederik De Graef (D)

Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States.

Rameen Shah (R)

Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.

Maaike de Vries (M)

Department of Pediatrics, Radboud University Medical Centre, Nijmegen, the Netherlands.

Austin Larson (A)

Department of Pediatrics, Section of Genetics, University of Colorado School of Medicine, Aurora, CO, United States.

Emma Glamuzina (E)

Adult and Paediatric National Metabolic Service, Auckland City Hospital, Auckland, New Zealand.

Eva Morava (E)

Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Department of Medical Genetics, University of Pecs Medical School, Pecs, Hungary. Electronic address: Morava-Kozicz.Eva@Mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH